Endonovo Therapeutics, Inc. is a biotechnology company, which engages in the development, manufacture, and distribution of medical devices focused on the rapid healing of wounds and reduction of pain, edema, and inflammation on and in the human body. The company is headquartered in Woodland Hills, California and currently employs 0 full-time employees. The company went IPO on 2012-03-09. The firm is focused on developing bioelectronic devices and cell therapies for regenerative medicine and is a commercial-stage developer of non-invasive wearable Electroceuticals therapeutic devices. The firm's portfolio of commercial and clinical-stage wearable Electroceuticals therapeutic devices addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and Central Nervous System (CNS) disorders, including traumatic brain injury (TBI), acute concussions, post- concussion syndrome, and multiple sclerosis. Its non-invasive Electroceutical therapeutic device, SofPulse, uses pulsed short-wave radiofrequency at 27.12 megahertz (MHz) used for the palliative treatment of soft tissue injuries, and post-operative pain and edema, as well as for the treatment of chronic wounds. The company offers an alternative, non-opioid treatment through its Electroceuticals systems.